JPRN-jRCT2080221526未知1 期
A Phase I Study of TS-1 in Combination with ABI-007 every three weeks in Patients with Unresectable or Recurrent Gastric Cancer
试验速览
- 阶段
- 1 期
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Signed, written informed consent.
- •- Patient has a histologically or cytologically confirmed gastric adenocarcinoma. Or patient has a clinically confirmed unresectable or recurrent gastric cancer.
- •- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
排除标准
- •- Patient who is contraindicated to TS-1 or Paclitaxel.(Refer to Package Insert).
- •- Patient has multiple cancer.
- •- Patient has a clinically significant medical history or disease complication.
研究者
相似试验
招募中
2 期
Phase II study of TS-1+CPT-11+BV followed by TS-1+L-OHP+BV in unresectable advanced colorectal cancer with RAS mutatioColorectal cancerJPRN-UMIN000014892iigata Colorectal Cancer Study Group50
尚未招募
1 期
Phase I and dose-finding study of TS-1 with Abraxane for metastatic breast cancermetastatic breast cancerJPRN-UMIN000006383Tokusima University Hospital12
已完成
不适用
A phase I/II study of preoperative TS-1 combined chemoradiation therapy for patients with large type 3 or type 4 gastric cancer (OGSG 1303)gastric cancerJPRN-UMIN000013821Osaka Gastrointestinal cancer chemotherapy Study Group (OGSG)10
已完成
不适用
Phase II study of a combination of TS-1 and TXL for advanced/recurrent gastric cancer patients with peritoneal metastasisPatients with gastric cancer and peritoneal metastasisJPRN-UMIN000000746OGSG30
进行中（未招募）
1 期
A clinical trial of a new drug known as Ti-061, that will take place in patients with tumors. Ti-061 will be assessed as a standalone drug as well as being assessed when taken with another drug, called Pembrolizumab.Advanced malignanciesMedDRA version: 19.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.1Level: PTClassification code 10066476Term: Haematological malignancySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004372-22-GBTioma Therapeutics, Inc.320